Welcome, Guest. Please login or register.
June 27, 2017, 04:55:26 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 49213
  • Total Topics: 3820
  • Online Today: 56
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 AM)
Users Online
Users: 1
Guests: 32
Total: 33

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Cancer Drug Works Regardless of Tumor Location  (Read 256 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Forum Moderators

  • Administrator
  • Member
  • Posts: 29
New Cancer Drug Works Regardless of Tumor Location
« on: June 05, 2017, 03:28:33 PM »
A new type of targeted cancer therapy shrinks tumors that carry a specific genetic mutation regardless of where they may be located in the body, researchers reported at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago.

Studies showed that 76 percent of people with 17 types of cancers responded to treatment with larotrectinib, an agent that acts against tumors with tropomyosin receptor kinase (TRK) fusions. Larotrectnib is the first cancer drug to be developed simultaneously for adult and pediatric populations, and treatment was effective in both groups.

“This really brings us into a new era where treatment is truly based on mutation, not location,” Sumanta Kumar Pal, MD, from City of Hope cancer center said at an ASCO press briefing.

Read more...
https://www.realhealthmag.com/article/cancer-drug-larotrectinib-clinical-trials

 


© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.